Fullerene-based antioxidants and neurodegenerative disorders

Parkinsonism & Related Disorders
Laura L DuganK L. O'Malley

Abstract

Water-soluble derivatives of buckminsterfullerene (C(60)) derivatives are a unique class of compounds with potent antioxidant properties. Studies on one class of these compounds, the malonic acid C(60) derivatives (carboxyfullerenes), indicated that they are capable of eliminating both superoxide anion and H(2)O(2), and were effective inhibitors of lipid peroxidation, as well. Carboxyfullerenes demonstrated robust neuroprotection against excitotoxic, apoptotic and metabolic insults in cortical cell cultures. They were also capable of rescuing mesencephalic dopaminergic neurons from both MPP(+) and 6-hydroxydopamine-induced degeneration. Although there is limited in vivo data on these compounds to date, we have previously reported that systemic administration of the C(3) carboxyfullerene isomer delayed motor deterioration and death in a mouse model of familial amyotrophic lateral sclerosis (FALS). Ongoing studies in other animal models of CNS disease states suggest that these novel antioxidants are potential neuroprotective agents for other neurodegenerative disorders, including Parkinson's disease.

References

Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·L L DuganT S Lin
Feb 29, 2000·Journal of Neurochemistry·M BisagliaG Schettini
May 2, 2000·Journal of Neuroscience Methods·K L QuickL L Dugan

❮ Previous
Next ❯

Citations

Mar 28, 2012·Fish Physiology and Biochemistry·Daiane da Silva AcostaLaura Alicia Geracitano
Nov 14, 2007·Pharmaceutical Research·Ljubica HarhajiVladimir Trajkovic
Jan 23, 2008·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jamie L GilmoreAlexander V Kabanov
Apr 25, 2012·European Journal of Drug Metabolism and Pharmacokinetics·Ivana VapaJovan K Popović
Mar 18, 2004·Bioorganic & Medicinal Chemistry Letters·Tao SunZhude Xu
Apr 11, 2013·Chemical Reviews·Manolis D Tzirakis, Michael Orfanopoulos
Dec 24, 2005·Nature Reviews. Neuroscience·Gabriel A Silva
Jan 26, 2010·Antioxidants & Redox Signaling·Ines Batinić-HaberleIvan Spasojević
May 13, 2010·Radiation Oncology·Aaron P BrownDeborah E Citrin
Aug 25, 2007·Nanomedicine·Beverly A RzigalinskiCourtney A Cohen
Apr 29, 2014·Journal of Nanobiotechnology·Azamal Husen, Khwaja Salahuddin Siddiqi
Jul 21, 2009·AJNR. American Journal of Neuroradiology·J M Provenzale, G A Silva
Feb 1, 1994·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Y MelamedM Frydman
Dec 13, 2002·Journal of Neuroscience Research·Aleph A Corona-MoralesLimei Zhang
Mar 10, 2012·Current Opinion in Structural Biology·Wataru ShinodaMichael L Klein
Jun 28, 2011·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Akram NezhadiMehdi Mehdizadeh
Apr 26, 2011·Ecotoxicology and Environmental Safety·Boris JovanovićDušan Palić
Oct 5, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Shigeki InuiSatoshi Itami
Aug 31, 2010·Regulatory Toxicology and Pharmacology : RTP·Karin AschbergerFrans M Christensen
Jun 3, 2009·Progress in Neurobiology·Girish ModiDinesh Naidoo
Feb 19, 2009·Nanomedicine : Nanotechnology, Biology, and Medicine·Zhiguo ZhouChristopher L Kepley
Mar 11, 2008·Parkinsonism & Related Disorders·G Linazasoro, UNKNOWN Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS)
Feb 27, 2008·Toxicology and Applied Pharmacology·Crystal Y UsenkoRobert L Tanguay
Sep 11, 2007·The Medical Clinics of North America·K John MorrowChiming Wei
Jan 9, 2007·Journal of the Neurological Sciences·Pamela G GrossLeslie P Weiner
Nov 3, 2006·Neurobiology of Aging·Kevin L QuickLaura L Dugan
Apr 18, 2007·Experimental Dermatology·Filomena ChiricoCarlo Pincelli
Mar 15, 2006·Chemistry : a European Journal·Roger F EnesLuca Valgimigli
Dec 16, 2011·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Marco A ZarbinRobert Ritch
Oct 13, 2010·Biotechnology and Bioengineering·Vladimir ReukovAlexey Vertegel
Feb 2, 2010·Chemistry : a European Journal·Sílvia OsunaMiquel Solà

❮ Previous
Next ❯

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.